Development of an assay for cellular efflux of pharmaceutically active agents and its relevance to understanding drug interactions

Experimental Hematology

Volumn 52, Issue , 2017, Pages 65-71

  Valdez, Benigno C ^a   Hassan, Moustapha ^b   Andersson, Borje S ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

5 CARBOXYFLUORESCEIN DIACETATE ACETOXYMETHYL ESTER; 6 CARBOXYFLUORESCEIN; ALKYLATING AGENT; CHLORAMBUCIL; DNA; ESTERASE; ETACRYNIC ACID; EVEROLIMUS; FLUORESCENT DYE; GLUTATHIONE; KETOCONAZOLE; MULTIDRUG RESISTANCE ASSOCIATED PROTEIN 1; PERFOSFAMIDE; RAPAMYCIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG; VERAPAMIL; VERLUKAST; 4-CARBOXYFLUORESCEIN; 5-CARBOXYFLUORESCEIN DIACETATE ACETOXYMETHYL ESTER; BUSULFAN; CYCLOPHOSPHAMIDE; FLUORESCEIN DERIVATIVE; MELPHALAN; MULTIDRUG RESISTANCE PROTEIN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEIN 1;

ARTICLE; CELL LEVEL; CELL SURVIVAL; CELL TRANSPORT; CONTROLLED STUDY; CYTOTOXICITY; DRUG DETERMINATION; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; DRUG SCREENING; DRUG STRUCTURE; DRUG TRANSPORT; FLOW CYTOMETRY; GLUTATHIONE METABOLISM; LEUKEMIA CELL LINE; LYMPHOMA CELL LINE; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; CHEMISTRY; DRUG EFFECTS; DRUG INTERACTION; HUMAN; METABOLISM; PROCEDURES; REPRODUCIBILITY; TRANSPORT AT THE CELLULAR LEVEL; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, ALKYLATING; BIOLOGICAL TRANSPORT; BUSULFAN; CELL LINE, TUMOR; CELL SURVIVAL; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; DRUG INTERACTIONS; ETHACRYNIC ACID; EVEROLIMUS; FLOW CYTOMETRY; FLUORESCEINS; HUMANS; KETOCONAZOLE; MELPHALAN; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; REPRODUCIBILITY OF RESULTS; SIROLIMUS;

EID: 85020415178     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2017.04.011     Document Type: Article

References (25)

1. Hassan, M., Oberg, G., Björkholm, M., Wallin, I., Lindgren, M., Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 33 (1993), 181–186.
2. Buggia, I., Zecca, M., Alessandrino, E.P., et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 16 (1996), 2083–2088.
3. Hassan, M., Ljungman, P., Ringdén, O., et al. The effect of busulphan on the pharmacokinetics of cyclophosphamide and its 4-hydroxy metabolite: Time interval influence on therapeutic efficacy and therapy-related toxicity. Bone Marrow Transplant 25 (2000), 915–924.
4. Sweiss, K., Patel, P., Rondelli, D., Deferasirox increases Bu blood concentrations. Bone Marrow Transplant 47 (2012), 315–316.
5. Nilsson, C., Aschan, J., Hentschke, P., Ringden, O., Ljungman, P., Hassan, M., The effect of metronidazole on busulfan pharmacokinetics in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 31 (2003), 429–435.
6. Gulbis, A.M., Culotta, K.S., Jones, R.B., Andersson, B.S., Busulfan and metronidazole: An often forgotten but significant drug interaction. Ann Pharmacother, 45, 2011, e39.
7. Jolivot, P.A., Poinsignon, V., Paci, A., et al. A case of melphalan sustained accumulation in an 80-year old patient. Int J Clin Pharm 37 (2015), 984–987.
8. Castellino, S.M., Friedman, H.S., Elion, G.B., et al. Flunarizine enhancement of melphalan activity against drug-sensitive/resistant rhabdomyosarcoma. Br J Cancer 71 (1995), 1181–1187.
9. Giallongo, C., La Cava, P., Tibullo, D., et al. Imatinib increases cytotoxicity of melphalan and their combination allows an efficient killing of chronic myeloid leukemia cells. Eur J Haematol 86 (2011), 216–225.
10. Valdez, B.C., Murray, D., Ramdas, L., et al. Altered gene expression in busulfan-resistant human myeloid leukemia. Leuk Res 32 (2008), 1684–1697.
11. Mosmann, T., Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods 65 (1983), 55–63.
12. Dogan, A.L., Legrand, O., Faussat, A.M., Perrot, J.Y., Marie, J.P., Evaluation and comparison of MRP1 activity with three fluorescent dyes and three modulators in leukemic cell lines. Leuk Res 28 (2004), 619–622.
13. Tsuruo, T., Iida, H., Yamashiro, M., Tsukagoshi, S., Sakurai, Y., Enhancement of vincristine- and adriamycin-induced cytotoxicity by verapamil in P388 leukemia and its sublines resistant to vincristine and adriamycin. Biochem Pharmacol 31 (1982), 3138–3140.
14. Gekeler, V., Ise, W., Sanders, K.H., Ulrich, W.R., Beck, J., The leukotriene LTD4 receptor antagonist MK571 specifically modulates MRP associated multidrug resistance. Biochem Biophys Res Commun 208 (1995), 345–352.
15. Slattery, J.T., Sanders, J.E., Buckner, C.D., et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 16 (1995), 31–42.
16. Hassan, M., Andersson, B.S., Role of pharmacogenetics in busulfan/cyclophosphamide conditioning therapy prior to hematopoietic stem cell transplantation. Pharmacogenomics 14 (2013), 75–87.
17. Armstrong, J.S., Steinauer, K.K., Hornung, B., et al. Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ 9 (2002), 252–263.
18. Tagde, A., Singh, H., Kang, M.H., Reynolds, C.P., The glutathione synthesis inhibitor buthionine sulfoximine synergistically enhanced melphalan activity against preclinical models of multiple myeloma. Blood Cancer J, 4, 2014, e229.
19. Brade, W.P., Seeber, S., Herdrich, K., Comparative activity of ifosfamide and cyclophosphamide. Cancer Chemother Pharmacol 18 Suppl 2 (1986), 1–9.
20. Ludeman, S.M., The chemistry of the metabolites of cyclophosphamide. Curr Pharm Des 5 (1999), 627–643.
21. Lind, M.J., McGown, A.T., Hadfield, J.A., Thatcher, N., Crowther, D., Fox, B.W., The effect of ifosfamide and its metabolites on intracellular glutathione levels in vitro and in vivo. Biochem Pharmacol 38 (1989), 1835–1840.
22. Peters, R.H., Ballard, K., Oatis, J.E., Jollow, D.J., Stuart, R.K., Cellular glutathione as a protective agent against 4-hydroperoxycyclophosphamide cytotoxicity in K-562 cells. Cancer Chemother Pharmacol 26 (1990), 397–402.
23. Meier, T., Allenbacher, A., Mueller, E., et al. Ifosfamide induced depletion of glutathione in human peripheral blood lymphocytes and protection by mesna. Anticancer Drugs 5 (1995), 403–409.
24. Morrow, C.S., Smitherman, P.K., Diah, S.K., Schneider, E., Townsend, A.J., Coordinated action of glutathione S-transferases (GSTs) and multidrug resistance protein 1 (MRP1) in antineoplastic drug detoxification: Mechanism of GST A1-1- and MRP1-associated resistance to chlorambucil in MCF7 breast carcinoma cells. J Biol Chem 273 (1998), 20114–20120.
25. Morrow, C.S., Smitherman, P.K., Townsend, A.J., Combined expression of multidrug resistance protein (MRP) and glutathione S-transferase P1-1 (GSTP1-1) in MCF7 cells and high level resistance to the cytotoxicities of ethacrynic acid but not oxazaphosphorines or cisplatin. Biochem Pharmacol 56 (1998), 1013–1022.